Aeva Technologies, Inc. — Form 8-K Summary
Business Context and Reporting Period
Aeva Technologies, Inc. designs and develops sensing and perception technology. This Form 8-K reports an NYSE continued-listing deficiency notice received on September 21, 2023; the report was signed and furnished on September 22, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial results.
Material Change
- The NYSE notified Aeva that its common stock had an average closing price below $1.00 per share over a consecutive 30-trading-day period, violating Section 802.01C of the NYSE Listed Company Manual.
- The common stock remains listed and traded on the NYSE during the cure period, subject to compliance with other continued-listing requirements.
- The notice does not immediately affect the Company’s business operations or SEC reporting obligations.
Outlook, Risks, and Contingencies
- Aeva must notify the NYSE within 10 business days of receiving the notice regarding its intent to cure the deficiency. The Company stated that it intends to consider available alternatives to regain compliance.
- The Company has a six-month cure period. It may regain compliance if, on the last trading day of a calendar month during that period, its closing share price is at least $1.00 and its average closing price over the preceding 30 trading days is at least $1.00.
- If the deficiency is not cured, the Company could face additional NYSE action, including potential suspension or delisting; the filing does not state that such action has occurred or is certain.
- The Company issued a September 22, 2023 press release regarding the notice and its intention to regain compliance. The press release was furnished, not filed, under the Exchange Act.
Investor Verification Points
- Verify the commencement date and deadline of the six-month cure period with the NYSE notice.
- Monitor Aeva’s closing share price and 30-trading-day average against the $1.00 requirements.
- Review any subsequent filings for a reverse stock split, other capital-markets action, NYSE determination, or delisting proceedings.
- Assess the Company’s separate financial condition and liquidity disclosures, which are not included in this 8-K.